NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT04458922 2026-04-13
Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06942442 2025-12-26
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Recruiting
NCT07153887 2025-09-30
Vebreltinib for Advanced or Metastatic CCS
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT03132155 2024-05-24
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
NantPharma, LLC
Phase 2 Terminated
NCT04274023 2024-02-01
ACCeSs
Italian Sarcoma Group
Phase 2 Terminated
NCT01524926 2023-12-11
CREATE
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT03989596 2021-02-01
SINDIR
Maria Sklodowska-Curie National Research Institute of Oncology
Phase 2 Unknown
NCT02968303 2020-06-05
COWBOY
Radboud University Medical Center
Phase 2 Unknown
NCT00557609 2013-02-08
Phase 2 Study in Patients With MiT Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 2 Completed